Alzheimer's Drug Examined for Use in Treatment-Resistant Depression
the Psychiatry Advisor take:
Researchers at the University of Texas Southwestern Medical Center are conducting research into using the dementia drug Namenda (memantine) as a therapy for treatment-resistant depression. Memantine, acts on the brain’s NMDA receptors, which are known to play a role in depression. The research could eventually lead to a treatment that blocks NMDA receptors and better controls depression with fewer side effects.
Memantine is chemically similar to ketamine, which is known to produce a fast-acting antidepressant effect in patients. However, ketamine’s other effects and recreational use make it unable to use for depression. But memantine reacts with the same brain receptors as ketamine, though researchers have found that it doesn’t produce the same antidepressant effect.
Identifying Fast-Acting Treatments for Resistant Depression
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Nomophobia: The Modern-Day Pathology
- Transdermal Nicotine Boosts Mood and Cognitive Function in Late-Life Depression
- Emerging Theories in the Pathophysiology of MDD: Could the Opioid System Be Involved?
- Ketamine Infusions Reduce Suicidal Ideation in Depression: Characterizing Different Responses
- Cognitive Behavioral Therapy May Alter Suicidal Ideation in Anxiety Disorders
- Text Message Reminders Improve Medication Adherence in Bipolar I Disorder
- Improving Medication Adherence in ADHD Lowers Risk for Oppositional Defiant Disorder, Conduct Disorder in Adulthood
- High Suicidality Among Children With ADHD Mediated by Family Functioning, Psychiatry Comorbidities
- Pilot Study Investigates Lithium vs Quetiapine for Bipolar Spectrum Disorder
- How Personalized Hospital Ratings May Drive Patient-Specific Care in the Digital Age